Evidence map›Paper›PMID 31354820›Full record

ReviewJournal of oncology2019

Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights.

Giandomenico Roviello, Alberto D'Angelo, Raheleh Roudi, Roberto Petrioli, Enrico Mini

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Second line of treatment for HER2-positive gastric cancer: an evolving issue.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Giandomenico RovielloDepartment of Health Sciences, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy.ORCID https://orcid.org/0000-0001-5504-8237
Alberto D'AngeloDepartment of Biology and Biochemistry, University of Bath, Bath BA2 7AY, UK.
Raheleh RoudiOncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran.
Roberto PetrioliMedical Oncology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
Enrico MiniDepartment of Health Sciences, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy.
University of Florence · ITIran University of Medical Sciences · IRUniversity of Bath · GBUniversity of Siena · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastatic gastric cancer is still a disease with a poor prognosis. Recently, different novel agents (e.g., apatinib, nivolumab, TAS-102) have demonstrated a survival advantage compared with placebo for patients with heavily pretreated metastatic gastric cancer. Although the possible availability of active agents may be a desirable option in a very poor therapeutic scenario, clinical data from the recent studies with these drugs raise yet controversial issues. The purpose of this review is to briefly summarize the results of these novel drugs focusing on the limitations that bring some shadows on their positive therapeutic results.

Identifiers

PMID31354820
PMCPMC6637676
OpenAlexW2953722844

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.